Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Noxopharm.
RELATED STOCKHEAD STORIES
Health & Biotech
Aussie biotechs join crusade for COVID-19 cure
Health & Biotech
Check up: COVID-19 is back in fashion
Experts
Scopo’s health powerplays: Clinical trials are back
Health & Biotech
Check up: Making it in America
Health & Biotech
COVID-19 treatments are a better bet than a vaccine
News
Rise and Shine: What you need to know before the ASX opens
News
Lunchtime ASX Small Cap Wrap: Oily to bed, oily to rise?
Health & Biotech
Noxopharm wants to test its anti-prostate cancer drug against COVID-19
Health & Biotech
Health: Noxopharm climbs 40pc after US FDA green lights trials of prostate drug
Health & Biotech
Health Kick Podcast: Skyrocketing prescription prices and Trump’s plan for the drug market
IPO Watch
IPO Watch: Noxopharm spin-off Nyrada gains 17.5pc on ASX debut
Health & Biotech
Health: Antisense’s anti-muscular dystrophy drug just took a big step
Health & Biotech
Health: Opthea’s taking its successful anti-AMD drug to a 1,320 patient phase III trial; raises $50m
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Noxopharm reckons its cancer-fighting Veyonda treatment could be a winner for late-stage patients
Health & Biotech
Health: Cross-continental expansion moves shares for germ killer Zoono
Health & Biotech
